Announcements Trials

Browse Landscape

Status

Completed 727 Recruiting 266 Terminated 171 Unknown 159 Active not recruiting 112 Withdrawn 60 Not yet recruiting 44 Enrolling by invitation 9 Suspended 7 No longer available 6 Available 6 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 11 Carcinoma, Non-Small-Cell Lung 11 Neoplasms 8 Prostatic Neoplasms 7 Multiple Myeloma 6 Breast Neoplasms 6 Leukemia, Myeloid, Acute 4 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large B-Cell, Diffuse 3 Lung Neoplasms 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Lambert-Eaton Myasthenic Syndrome 3 HER2-positive Breast Cancer 3 Glioma 3 Carcinoma, Medullary 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Pheochromocytoma 2 Paraganglioma 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Myasthenic Syndromes, Congenital 2 Lymphoma 2 Liver Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia 2 Head and Neck Neoplasms 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Sarcoma × Clear all

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and Company

Approved for marketing

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡